Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C870
http://purl.obolibrary.org/obo/NCIT_C870
|
|---|---|
| Preferred Name | Thalidomide |
| Definitions |
A synthetic derivative of glutamic acid (alpha-phthalimido-glutarimide) with teratogenic, immunomodulatory, anti-inflammatory and anti-angiogenic properties. Thalidomide acts primarily by inhibiting both the production of tumor necrosis factor alpha (TNF-alpha) in stimulated peripheral monocytes and the activities of interleukins and interferons. This agent also inhibits polymorphonuclear chemotaxis and monocyte phagocytosis. In addition, thalidomide inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), thereby inhibiting angiogenesis.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A synthetic derivative of glutamic acid (alpha-phthalimido-glutarimide) with teratogenic, immunomodulatory, anti-inflammatory and anti-angiogenic properties. Thalidomide acts primarily by inhibiting both the production of tumor necrosis factor alpha (TNF-alpha) in stimulated peripheral monocytes and the activities of interleukins and interferons. This agent also inhibits polymorphonuclear chemotaxis and monocyte phagocytosis. In addition, thalidomide inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), thereby inhibiting angiogenesis. |
|---|---|
| prefLabel | Thalidomide
|
| label | Thalidomide
|
| CHEBI_ID | CHEBI:9513
|
| PDQ_Closed_Trial_Search_ID | 42332
|
| code | C870
|
| Has_Target | |
| prefixIRI | NCIT:C870
|
| in_subset |
See more
See less
|
| Display_Name | Thalidomide
|
| Preferred_Name | Thalidomide
|
| FDA_UNII_Code | 4Z8R6ORS6L
|
| Contributing_Source |
CTRP
FDA
|
| Chemical_Formula | C13H10N2O4
|
| Maps_To | Thalidomide
|
| CAS_Registry | 50-35-1
|
| NSC Number | 66847
|
| NCI_Drug_Dictionary_ID | 42332
|
| Legacy Concept Name | Thalidomide
|
| type | |
| ALT_DEFINITION | A drug that is used to treat multiple myeloma in patients who have just been diagnosed, and a painful skin disease related to leprosy. It is also being studied in the treatment of other types of cancer. Thalomid belongs to the family of drugs called angiogenesis inhibitors.
|
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 42332
|
| Accepted_Therapeutic_Use_For | Aphthous stomatitis; Crohns disease; cutaneous manifestations of erythema nodosum leprosum; GVHD; HIV-associated wasting syndrome; Karposi sarcoma; lepromatous leprosy; multiple myeloma; mycobacterium tuberculosis and nontuberculosis; primary brain tumors
|
| Semantic_Type |
Organic Chemical
Pharmacologic Substance
|
| UMLS_CUI | C0039736
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |